and Xenobiotic Metabolism and Utility in Understanding Drug and Human Cytochrome P 450 1 A 1 Structure Protein Structure and Folding

[1]  F. Guengerich,et al.  Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. , 1995, Chemical research in toxicology.

[2]  F. Guengerich,et al.  Cytochrome P450 activation of arylamines and heterocyclic amines. , 2005, Annual review of pharmacology and toxicology.

[3]  Y. Chun,et al.  Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  H. Yamazaki,et al.  Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[5]  G J Kleywegt,et al.  Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.

[6]  Eric F. Johnson,et al.  Human CYP 2 D 6 Structure 1 CRYSTAL STRUCTURE OF HUMAN CYTOCHROME P 450 2 D 6 WITH PRINOMASTAT BOUND , 2012 .

[7]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[8]  R. Tukey,et al.  Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. , 1994, Archives of biochemistry and biophysics.

[9]  M. Varner,et al.  In utero tobacco exposure epigenetically modifies placental CYP1A1 expression. , 2010, Metabolism: clinical and experimental.

[10]  F. Guengerich,et al.  Contributions of human enzymes in carcinogen metabolism. , 2012, Chemical research in toxicology.

[11]  M. Burke,et al.  Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. , 2000, Toxicology.

[12]  Mark D. Paulsen,et al.  Predicting the product specificity and coupling of cytochrome P450cam , 1992, J. Comput. Aided Mol. Des..

[13]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[14]  Eric F. Johnson,et al.  Structural Characterization of the Complex between α-Naphthoflavone and Human Cytochrome P450 1B1* , 2010, The Journal of Biological Chemistry.

[15]  T. Shimada,et al.  Recombinant human cytochrome P450 1B1 expression in Escherichia coli. , 1998, Archives of biochemistry and biophysics.

[16]  K. Battaile,et al.  Human Cytochrome P450 2E1 Structures with Fatty Acid Analogs Reveal a Previously Unobserved Binding Mode* , 2010, The Journal of Biological Chemistry.

[17]  I. A. D. de Graaf,et al.  Induction of Metabolism and Transport in Human Intestine: Validation of Precision-Cut Slices as a Tool to Study Induction of Drug Metabolism in Human Intestine in Vitro , 2008, Drug Metabolism and Disposition.

[18]  D. Spandidos,et al.  Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention , 2009, BMC Cancer.

[19]  C David Stout,et al.  Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.

[20]  G. Szklarz,et al.  Application of Molecular Modeling for Prediction of Substrate Specificity in Cytochrome P450 1A2 Mutants , 2008, Drug Metabolism and Disposition.

[21]  D. Bandyopadhyay,et al.  Differential induction of CYP1A1 and CYP1B1 by benzo[a]pyrene in oral squamous cell carcinoma cell lines and by tobacco smoking in oral mucosa. , 2009, Oral oncology.

[22]  Spencer S. Ericksen,et al.  Preferred Binding Orientations of Phenacetin in CYP1A1 and CYP1A2 Are Associated with Isoform-Selective Metabolism , 2012, Drug Metabolism and Disposition.

[23]  Spencer S Ericksen,et al.  The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. , 2004, Archives of biochemistry and biophysics.

[24]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[25]  T. Shimada,et al.  Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1 , 2004, Cancer science.

[26]  Tetsuo Satoh,et al.  Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. , 2003, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[27]  Spencer S. Ericksen,et al.  Regiospecificity of Human Cytochrome P450 1A1-Mediated Oxidations: The Role of Steric Effects , 2005, Journal of biomolecular structure & dynamics.

[28]  Eric F. Johnson,et al.  Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain , 2008, Proceedings of the National Academy of Sciences.

[29]  Spencer S Ericksen,et al.  Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: case of residue 382. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[30]  Tsutomu Shimada,et al.  Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. , 2006, Drug metabolism and pharmacokinetics.

[31]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[32]  Spencer S. Ericksen,et al.  Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. , 2004, Biochemical pharmacology.

[33]  Shu-Feng Zhou,et al.  Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2 , 2009, The AAPS Journal.

[34]  J. Doehmer,et al.  Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1. , 2002, Mutagenesis.

[35]  G. Lushington,et al.  Key Residues Controlling Binding of Diverse Ligands to Human Cytochrome P450 2A Enzymes , 2009, Drug Metabolism and Disposition.

[36]  G. Szklarz,et al.  Molecular Modeling of Cytochrome P450 1A1: Enzyme-Substrate Interactions and Substrate Binding Affinities , 2002, Journal of biomolecular structure & dynamics.

[37]  P. Cooper,et al.  Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo , 2003, British Journal of Cancer.

[38]  R. Caccavale,et al.  Cytochromes P4501 (CYP1): catalytic activities and inducibility by diesel exhaust particle extract and benzo[a]pyrene in intact human lung ex vivo. , 2010, Toxicology.

[39]  O. Hankinson.  The aryl hydrocarbon receptor complex. , 1995, Annual review of pharmacology and toxicology.

[40]  G. Ferron,et al.  Quantitation of cytochrome P450 mRNA levels in human skin. , 2003, Analytical biochemistry.

[41]  Xiaochao Ma,et al.  METABOLISM OF MELATONIN BY HUMAN CYTOCHROMES P450 , 2005, Drug Metabolism and Disposition.

[42]  Christus,et al.  A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins , 2022 .

[43]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[44]  Significant Increase in Phenacetin Oxidation on L382V Substitution in Human Cytochrome P450 1A2 , 2010, Drug Metabolism and Disposition.

[45]  R. Tukey,et al.  Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. , 1997, Carcinogenesis.

[46]  L. Loeb,et al.  Environmental and chemical carcinogenesis. , 2004, Seminars in cancer biology.

[47]  A G Leslie,et al.  Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .

[48]  P. Beaune,et al.  Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. , 1992, Molecular pharmacology.

[49]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[50]  Weihua Li,et al.  Functional role of residues in the helix B' region of cytochrome P450 2B1. , 2005, Archives of biochemistry and biophysics.

[51]  F. Curriero,et al.  Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. , 2004, Toxicology and applied pharmacology.

[52]  Slobodan Petar Rendic.  Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[53]  F. Berthou,et al.  Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. , 2004, Biochemical pharmacology.

[54]  Jaime Pascual,et al.  Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules. , 2012, Biochemistry.

[55]  F. Guengerich,et al.  Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P450 1A2. , 1998, Chemical research in toxicology.

[56]  J. Reid,et al.  Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[58]  F. Guengerich,et al.  Resveratrol is a selective human cytochrome P450 1A1 inhibitor. , 1999, Biochemical and biophysical research communications.